Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
In this medfyle
Tirzepatide improves beta-cell function and insulin sensitivity.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This summary is based upon an article appearing in the Endocrine Society journal entitled The Journal of Clinical Endocrinology & Metabolism published by Oxford University Press and was created by GlobalPort (International) Limited. Neither Oxford University Press nor the Endocrine Society takes any responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Raghu G. Mirmira, MD, PhD,
Original article:
Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Kevin Duffin, Zvonko Milicevic, Axel Haupt, Deborah A Robins, Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 2, February 2021, Pages 388–396, https://doi.org/10.1210/clinem/dgaa863
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of Endocrine Society/Oxford University Press.
This activity is supported by an educational grant from Lilly.
